BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6143969)

  • 1. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man.
    Gresele P; Deckmyn H; Arnout J; Lemmens J; Janssens W; Vermylen J
    Lancet; 1984 May; 1(8384):991-4. PubMed ID: 6143969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
    Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
    Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients.
    Riess H; Höfling B; von Arnim T; Hiller E
    Thromb Res; 1986 Apr; 42(2):235-45. PubMed ID: 3012819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiaggregatory effects of thromboxane receptor antagonists in vivo.
    Darius H; Lefer AM
    Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets.
    Berrettini M; De Cunto M; Parise P; Grasselli S; Nenci GG
    Eur J Clin Pharmacol; 1990; 39(5):495-500. PubMed ID: 1963845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K; Halushka PV; Yan YT; Wong PY
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eicosapentaenoic acid and docosahexaenoic acid are antagonists at the thromboxane A2/prostaglandin H2 receptor in human platelets.
    Swann PG; Venton DL; Le Breton GC
    FEBS Lett; 1989 Jan; 243(2):244-6. PubMed ID: 2537230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet desensitization by arachidonic acid is associated with the suppression of endoperoxide/thromboxane A2 binding to the membrane receptor.
    Sato T; Hashizume T; Nakao K; Akiba S; Fujii T
    Biochim Biophys Acta; 1989 Aug; 992(2):168-73. PubMed ID: 2503041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets.
    Hamid-Bloomfield S; Whittle BJ
    Br J Pharmacol; 1986 Aug; 88(4):931-6. PubMed ID: 3017497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
    Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
    J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of endoperoxides in arachidonic acid-induced vasoconstriction in the isolated perfused kidney of the rat.
    Quilley J; McGiff JC; Nasjletti A
    Br J Pharmacol; 1989 Jan; 96(1):111-6. PubMed ID: 2522332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the mechanism of the prolonged action in man of GR32191, a thromboxane receptor antagonist.
    Ritter JM; Doktor HS; Benjamin N; Barrow SE; Stewart-Long P
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():351-4. PubMed ID: 1825568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock.
    Bitterman H; Yanagisawa A; Lefer AM
    Circ Shock; 1986; 20(1):1-11. PubMed ID: 2945667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference of the thromboxane antagonist SK&F 88046 with platelet activation and subsequent desensitization by arachidonic acid and the thromboxane mimetics U46619 and EP171.
    Vargaftig B; Joseph D; Hatmi M
    Thromb Res; 1987 May; 46(4):509-17. PubMed ID: 3039684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
    Lumley P; White BP; Humphrey PP
    Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the prostaglandin H2/thromboxane A2 antagonist BM 13.177 on human platelets.
    Patscheke H; Stegmeier K
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():371-3. PubMed ID: 3159225
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of ethanol on human platelets stimulated with platelet-activating factor, a biologically active ether phospholipid.
    Baker RC; Fish HT; Fitzpatrick FA
    Alcohol Clin Exp Res; 1989 Dec; 13(6):824-8. PubMed ID: 2557776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
    Harris RH; Nichols R; Schmeling JW; Ramwell PW
    Thromb Res; 1981 Sep; 23(6):521-32. PubMed ID: 6798707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.